Akebia Ther is a drug manufacturers - specialty & generic business based in the US. Akebia Ther shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.82 – an increase of 1.68% over the previous week. Akebia Ther employs 167 staff and has a trailing 12-month revenue of around $169.9 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.82 |
|---|---|
| 52-week range | $0.80 - $2.48 |
| 50-day moving average | $1.49 |
| 200-day moving average | $1.40 |
| Wall St. target price | $5.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.22 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.79 from 2024-11-20
| 1 week (2024-11-14) | -3.76% |
|---|---|
| 1 month (2024-10-21) | 30.66% |
| 3 months (2024-08-21) | 20.13% |
| 6 months (2024-05-21) | 58.41% |
| 1 year (2023-11-21) | 81.73% |
|---|---|
| 2 years (2022-11-21) | 601.96% |
| 3 years (2021-11-19) | 2.78 |
| 5 years (2019-11-21) | 3.46 |
Valuing Akebia Ther stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Akebia Ther's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Akebia Ther's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.4 million.
The EBITDA is a measure of a Akebia Ther's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $169.9 million |
|---|---|
| Gross profit TTM | $140 million |
| Return on assets TTM | -9.37% |
| Return on equity TTM | -553.45% |
| Profit margin | -27.07% |
| Book value | $-0.24 |
| Market Capitalization | $405.8 million |
TTM: trailing 12 months
We're not expecting Akebia Ther to pay a dividend over the next 12 months.
Over the last 12 months, Akebia Ther's shares have ranged in value from as little as $0.8 up to $2.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Ther's is 0.734. This would suggest that Akebia Ther's shares are less volatile than average (for this exchange).
Akebia Therapeutics, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.